Cardiovascular Consequences of Sickle Cell Disease

References

• Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease. JAMA. 2022;328(1):57. doi:10.1001/jama.2022.10233
   PubMed Web of Science ®Google Scholar
• Wood KC, Gladwin MT, Straub AC. Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure. Heart. 2020;106(8):562–568. doi:10.1136/heartjnl-2019-314810
   PubMed Web of Science ®Google Scholar
• Hayes MM, Vedamurthy A, George G, et al. Pulmonary hypertension in sickle cell disease. Ann Am Thorac Soc. 2014;11(9):1488–1489. doi:10.1513/AnnalsATS.201408-405CME
   PubMedGoogle Scholar
• Steppan J, Tran HT, Bead VR, et al. Arginase inhibition reverses endothelial dysfunction, pulmonary hypertension, and vascular stiffness in transgenic sickle cell mice. Anesth Analg. 2016;123(3):652–658. doi:10.1213/ANE.0000000000001378
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010. doi:10.1038/nrdp.2018.10
   PubMedGoogle Scholar
• Langer HF, Chavakis T. Leukocyte – endothelial interactions in inflammation. J Cell Mol Med. 2009;13(7):1211–1220. doi:10.1111/j.1582-4934.2009.00811.x
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886–895. doi:10.1056/NEJMoa035477
   PubMed Web of Science ®Google Scholar
• Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfusion. 2014;30(2):91–96. doi:10.1007/s12288-013-0261-4
   PubMed Web of Science ®Google Scholar
• Migotsky M, Beestrum M, Badawy SM. Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and L-glutamine. Pharmacy. 2022;10(5). doi:10.3390/pharmacy10050123
   Web of Science ®Google Scholar
• Leibovitch JN, Tambe AV, Cimpeanu E, et al. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: hype or hope? Blood Rev. 2022;53:100925. doi:10.1016/j.blre.2021.100925
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale JF. Gene therapy for sickle cell disease. Hematology. 2023;2023(1):542–547. doi:10.1182/hematology.2023000487
   PubMedGoogle Scholar
• Ogu UO, Badamosi NU, Camacho PE, Freire AX, Adams-Graves P. Management of sickle cell disease complications beyond acute chest syndrome. J Blood Med. 2021;12:101–114. doi:10.2147/JBM.S291394
   PubMed Web of Science ®Google Scholar
• Sheikh AB, Nasrullah A, Lopez ED, et al. Sickle cell disease-induced pulmonary hypertension: a review of pathophysiology, management, and current literature. Pulse. 2021;9(3–4):57–63. doi:10.1159/000519101
   PubMedGoogle Scholar
• Fonseca GHH, Souza R, Salemi VMC, Jardim CVP, Gualandro SFM. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112–118. doi:10.1183/09031936.00134410
   PubMed Web of Science ®Google Scholar
• Klings ES, Machado RF, Barst RJ, et al. An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727–740. doi:10.1164/rccm.201401-0065ST
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219–1263. doi:10.1183/09031936.00139009
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–D41. doi:10.1016/j.jacc.2013.10.029
   PubMed Web of Science ®Google Scholar
• Humbert M, Montani D, Evgenov OV, Simonneau G. Definition and classification of pulmonary hypertension. Handb Exp Pharmacol. 2013;218:3–29.
   PubMedGoogle Scholar
• Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127(7):820–828. doi:10.1182/blood-2015-08-618561
   PubMed Web of Science ®Google Scholar
• Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;111(1):402–410. doi:10.1182/blood-2007-04-081703
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin. 2011;3(1):23–45. doi:10.1016/j.ccep.2010.10.012
   PubMedGoogle Scholar
• Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117(9):665–669. doi:10.1016/j.amjmed.2004.03.034
   PubMed Web of Science ®Google Scholar
• Aleem A, Jehangir A, Owais M, et al. Echocardiographic abnormalities in adolescent and adult Saudi patients with sickle cell disease. Saudi Med J. 2007;28(7):1072–1075.
   PubMed Web of Science ®Google Scholar
• Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254. doi:10.1001/jama.2012.358
   PubMed Web of Science ®Google Scholar
• Ramphul K, Ramphul Y, Verma R, Kumar N, Joynauth J. Cardiac arrhythmias during sickle cell disease crisis in the United States. Am J Cardiol. 2021;149:160–161. doi:10.1016/j.amjcard.2021.03.030
   PubMed Web of Science ®Google Scholar
• Kapoor A, Thakkar S, Battel L, et al. The prevalence and impact of arrhythmias in hospitalized patients with sickle cell disorders: a large database analysis. Blood. 2020;136(Supplement 1):5–6. doi:10.1182/blood-2020-142099
   Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• Hemnes AR, Forfia PR, Champion HC. Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. Int J Clin Pract. 2009;63:4–19. doi:10.1111/j.1742-1241.2009.02110.x
   Web of Science ®Google Scholar
• Savale L, Habibi A, Lionnet F, et al. Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. Eur Respir J. 2019;54(6):1900585. doi:10.1183/13993003.00585-2019
   PubMed Web of Science ®Google Scholar
• Ziyadah MS, Mansory EM, Alahwal HM, et al. Predisposing factors and incidence of venous thromboembolism among hospitalized patients with sickle cell disease. J Clin Med. 2023;12(20):6498. doi:10.3390/jcm12206498
   PubMed Web of Science ®Google Scholar
• Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272–1279. doi:10.1164/rccm.200610-1498OC
   PubMed Web of Science ®Google Scholar
• Sachdev V, Rosing DR, Thein SL. Cardiovascular complications of sickle cell disease. Trends Cardiovasc Med. 2021;31(3):187–193. doi:10.1016/j.tcm.2020.02.002
   PubMed Web of Science ®Google Scholar
• Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary Hypertension in CKD. Am J Kidney Dis. 2013;61(4):612–622. doi:10.1053/j.ajkd.2012.07.029
   PubMed Web of Science ®Google Scholar
• Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74(6):626–628. doi:10.1016/0002-9149(94)90760-9
   PubMed Web of Science ®Google Scholar
• Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101(4):1257–1261. doi:10.1182/blood-2002-03-0948
   PubMed Web of Science ®Google Scholar
• Patel U, Desai R, Hanna B, et al. Sickle cell disease‐associated arrhythmias and in‐hospital outcomes: insights from the National Inpatient Sample. J Arrhythm. 2020;36(6):1068–1073. doi:10.1002/joa3.12418
   PubMed Web of Science ®Google Scholar
• Chaurasia SP, Manvar R. Study of electrocardiographic and echocardiographic changes in sickle cell anaemia patients.
   Google Scholar
• Akgül F, Seyfeli E, Melek İ, et al. Increased QT dispersion in sickle cell disease: effect of pulmonary hypertension. Acta Haematol. 2007;118(1):1–6. doi:10.1159/000100929
   PubMed Web of Science ®Google Scholar
• Roberts PR, Green D. Arrhythmias in chronic kidney disease. Heart. 2011;97(9):766–773. doi:10.1136/hrt.2010.208587
   PubMed Web of Science ®Google Scholar